Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profilingAndrew H. Beck, Matt van de Rijn, Shirley Zhu et al.|Oncogene|2009Cited by 150
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohortsSiri H. Strand, Graham A. Colditz, Belén Rivero‐Gutiérrez et al.|Cancer Cell|2022Cited by 88
ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumourBadreddin Edris, Matt van de Rijn, Íñigo Espinosa et al.|The Journal of Pathology|2012Cited by 77